Next 10 |
home / stock / elan / elan articles
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco An...
NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Elanco Animal Heal...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigati...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco An...
SAN DIEGO, June 28, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elanco Animal Health Incor...
MONSEY, N.Y., June 28, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Elanco Animal Health Incorporat...
Elanco Animal Health Incorporated (NYSE:ELAN) stock is tumbling as the company released updates to the expected FDA approval timelines for Zenrelia...
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday. Shares of Levi Strauss & Co. (NYSE:LEVI) f...
Elanco Animal Health Incorporated (NYSE:ELAN) reported first-quarter adjusted EPS of $0.34, down 26% year over year, beating the con...
News, Short Squeeze, Breakout and More Instantly...
Elanco Animal Health Incorporated Company Name:
ELAN Stock Symbol:
NYSE Market:
Elanco Animal Health Incorporated Website:
NEW YORK CITY, NY / ACCESSWIRE / July 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities are encouraged to obtain additi...
2024-07-01 07:00:08 ET David Westenberg from Piper Sandler issued a price target of $16.00 for ELAN on 2024-07-01 06:25:00. The adjusted price target was set to $16.00. At the time of the announcement, ELAN was trading at $14.43. The overall price target consensus is at ...
Elanco Provides Innovation Update PR Newswire Major technical sections complete for Zenrelia, with FDA final approval on track for late in third quarter of 2024; updates on differentiation and safety Final FDA approval for Credelio Quattro now expected in the fo...